Endostatin-Encapsulated N-Succinyl-Chitosan Nanoparticles Inhabited the Growth of MCF-7 Cell

Yanrong Fan^*, Ye Li, Xuefei Xia

Nanjing University of Science and Technology, Nanjing, China.

DOI: 10.4236/oalib.1102083                

Abstract

A simple method was developed to synthesize the N-succinyl-chitosan (NSC) successfully. NSC was characterized by FTIR, ¹H NMR and element analysis. The NSC can form nanoparticles with TPP through electrostatic interaction. The morphology, particle size and zeta potential of the nanoparticle were investigated and showed a 100 - 200 nm in diameter with a positive potential 9.99 mv. The encapsulation efficiency of NSC-ES-NPs was 94.76 ± 0.05. The in vitro cell culture indicates that NSC has non-toxicity and cell-compatibility. NSC-ES-NPs show antitumor activity against MCF-7 cell. Our results demonstrate that NSC has great potential in the drug controlled release delivery.

Keywords

N-Succinyl-Chitosan, Nanoparticle, Endostatin

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Luo, H., Li, J. and Chen, X. (2010) Antitumor Effect of N-Succinyl-Chitosan Nanoparticles on K562 Cells. Biomedicine & Pharmacotherapy, 64, 521-526. http://dx.doi.org/10.1016/j.biopha.2009.09.002
[2]	Park, J.H., Saravanakumar, G., Kim, K., et al. (2010) Targeted Delivery of Low Molecular Drugs Using Chitosan and Its Derivatives. Advanced Drug Delivery Reviews, 62, 28-41. http://dx.doi.org/10.1016/j.addr.2009.10.003
[3]	Ying, G.Q., Yang, H., Yi, Y., et al. (2007) Relationships between the Molecular Structure and Moisture-Absorption and Moisture-Retention Abilities of Succinyl Chitosan. Polymer Bulletin, 59, 509-516. http://dx.doi.org/10.1007/s00289-007-0790-9
[4]	Sui, W., Wang, Y., Dong, S, et al. (2008) Preparation and Properties of an Amphiphilic Derivative of Succinyl-Chitosan. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 316, 171-175. http://dx.doi.org/10.1016/j.colsurfa.2007.09.016
[5]	Zhu, A.P., Chen, T., Yuan, L.H., Wu, H. and Lu, P. (2006) Synthesis and Characterization of N-Succinyl-Chitosan and Its Self-Assembly of Nanospheres. Carbohydrate Polymers, 66, 274-279. http://dx.doi.org/10.1016/j.carbpol.2006.03.014
[6]	Kato, Y., Onishi, H. and Machida, Y. (2001) Biological Characteristics of Lactosaminated N-Succinyl-Chitosan as a Liver-Specific Drug Carrier in Mice. Journal of Controlled Release, 70, 295-307. http://dx.doi.org/10.1016/S0168-3659(00)00356-4
[7]	Kato, Y., Onishi, H. and Machida, Y. (2001) Lactosaminated and Intact N-Succinyl-Chitosans as Drug Carriers in Liver Metastasis. International Journal of Pharmaceutics, 226, 93-106. http://dx.doi.org/10.1016/S0378-5173(01)00777-3
[8]	Asai, K., Kanazawa, H., Otani, K., et al. (2002) Imbalance between Vascular Endothelial Growth Factor and Endostatin Levels in Induced Sputum from Asthmatic Subjects. Journal of Allergy and Clinical Immunology, 110, 571-575. http://dx.doi.org/10.1067/mai.2002.127797
[9]	Qian, C.N., Zhang, C.Q., Guo, X., et al. (2000) Elevation of Serum Vascular Endothelial Growth Factor in Male Patients with Metastatic Nasopharyngeal Carcinoma. Cancer, 88, 255-261. http://dx.doi.org/10.1002/(SICI)1097-0142(20000115)88:2<255::AID-CNCR2>3.0.CO;2-N
[10]	Takeda, A., Shimada, H., Imaseki, H., et al. (2000) Clinical Significance of Serum Vascular Endothelial Growth Factor in Colorectal Cancer Patients: Correlation with Clinicopathological Factors and Tumor Markers. Oncology Reports, 7, 333-338. http://dx.doi.org/10.3892/or.7.2.333
[11]	Jones A, Fujiyama C, Turner K, et al. (2000) Elevated Serum Vascular Endothelial Growth Factor in Patients with Hormone-Escaped Prostate Cancer. BJU International, 85, 276-280. http://dx.doi.org/10.1046/j.1464-410x.2000.00432.x
[12]	Suzuki, M., Iizasa, T., Ko, E., et al. (2002) Serum Endostatin Correlates with Progression and Prognosis of Non-Small Cell Lung Cancer. Lung Cancer, 35, 29-34. http://dx.doi.org/10.1016/S0169-5002(01)00285-9
[13]	Folkman, J. (2006) Antiangiogenesis in Cancer Therapy—Endostatin and Its Mechanisms of Action. Experimental Cell Research, 312, 594-607. http://dx.doi.org/10.1016/j.yexcr.2005.11.015
[14]	O’Reilly, M.S., Boehm, T., Shing, Y., et al. (1997) Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth. Cell, 88, 277-285. http://dx.doi.org/10.1016/S0092-8674(00)81848-6
[15]	Nilsson, U.W. and Dabrosin, C. (2006) Estradiol and Tamoxifen Regulate Endostatin Generation via Matrix Metalloproteinase Activity in Breast Cancer in Vivo. Cancer Research, 66, 4789-4794. http://dx.doi.org/10.1158/0008-5472.CAN-05-4012
[16]	Abdollahi, A., Hahnfeldt, P., Maercker, C., et al. (2004) Endostatin’s Antiangiogenic Signaling Network. Molecular Cell, 13, 649-663. http://dx.doi.org/10.1016/S1097-2765(04)00102-9
[17]	Hajitou, A., Grignet, C., Devy, L., et al. (2002) The Antitumoral Effect of Endostatin and Angiostatin Is Associated with a Down-Regulation of Vascular Endothelial Growth Factor Expression in Tumor Cells. The FASEB Journal, 16, 1802-1804. http://dx.doi.org/10.1096/fj.02-0109fje